Newly approved targeted therapy sotorasib prolongs survival in KRAS G12C-mutated lung cancer

ABSTRACT #9003 HOUSTON – Results from the Phase II cohort of the CodeBreaK 100 study showed that treatment with the KRAS G12C inhibitor sotorasib achieved a 37.1% objective response rate and 12.5 months median overall survival in previously treated patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC), according to researchers from The University…

Social identity within the anti-vaccine movement

A study of more than 1,000 demographically representative participants found that about 22 percent of Americans self-identify as anti-vaxxers, and tend to embrace the label as a form of social identity. According to the study by researchers including Texas A&M University School of Public Health assistant professor Timothy Callaghan, 8 percent of this group “always”…